Lupin Expands U.S. Footprint with New Corporate Headquarters in New Jersey

Global pharmaceutical leader, Lupin Limited (Lupin), officially marked a major milestone in its United States operations with the inauguration of its new corporate offices on October 28, 2025. The new facility is strategically located at 100 Somerset Corporate Blvd in Bridgewater, New Jersey. This expansion significantly enhances Lupin’s existing presence in the state, which already includes established manufacturing and research facilities in Somerset.

The ribbon-cutting ceremony, a high-profile event, was attended by several distinguished guests. Leading government officials included New Jersey Governor Phil Murphy and Somerset County Commissioner Deputy Director Melonie Marano. Representing Lupin were top executives: Vinita Gupta (CEO), Spiro Gavaris (President, U.S. Generics), and Christoph Funke (Chief Technical Operations Officer).

Facility and Functions

The newly opened office spans approximately 18,000 square feet and is designed to centralize and accommodate various critical corporate functions. These include:

Commercial Operations
Human Resources (HR)
Finance
Legal
Marketing
Business Development
Research & Development (R&D)

Lupin initially established its presence in New Jersey in 2016 with the acquisition of a manufacturing facility in Somerset.

Statements on Partnership and Growth

New Jersey Governor Phil Murphy praised Lupin’s decision to deepen its roots in the state, stating that the expansion is “fully aligned with my administration’s priorities.” He emphasized that the investment helps in strengthening the state’s robust pharmaceutical industry, driving economic growth, and creating skilled jobs for New Jersey residents.

Vinita Gupta, CEO of Lupin, affirmed the state’s importance, recognizing New Jersey as a “stronghold for the biopharmaceutical industry.” She highlighted that the company’s comprehensive operations—covering corporate offices, manufacturing, and research facilities—have been “an important part of our U.S. growth and expansion.” This foundation, she noted, is essential to drive innovation and provide access to affordable, high-quality medications nationwide.

Spiro Gavaris, President, U.S. Generics, Lupin, specifically addressed the employment impact, stating, “Our NJ-based workforce now exceeds 300 employees, and we have plans to continue to grow.” He acknowledged New Jersey’s rich talent pool, particularly in the life sciences sector, and expressed eagerness to create more opportunities.

Somerset County Commissioner Deputy Director Melonie Marano also welcomed the expansion, calling Lupin a “long-valued member of our business community.” She noted that the company’s growth underscores the “exceptional talent, innovation and opportunities Somerset County has to offer.”

Reinforcing U.S. Commitment

Lupin’s Bridgewater expansion is part of a broader, significant investment strategy in the U.S. This commitment was recently underscored by the announcement of plans to construct a state-of-the-art manufacturing facility in Coral Springs, Florida. This Florida project is aimed at anchoring U.S. production of critical respiratory therapies, further reinforcing Lupin’s long-term dedication to pharmaceutical innovation and the U.S. healthcare ecosystem.